Advertisement

Topics

PubMed Journals Articles About "SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated" RSS

09:10 EDT 20th March 2019 | BioPortfolio

SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated articles that have been published worldwide.

More Information about "SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated" on BioPortfolio

We have published hundreds of SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated news stories on BioPortfolio along with dozens of SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated Clinical Trials and PubMed Articles about SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated Companies in our database. You can also find out about relevant SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated Drugs and Medications on this site too.

Showing "SeborrheaGlobal Manufacturers Marketed Phase Drugs Landscape 2017 Updated" PubMed Articles 1–25 of 15,000+

The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions.

As the name suggests, drug repurposing is a strategy to identify new therapeutic uses for marketed drugs, discontinued and/or shelved drugs, and drug candidates currently in clinical development. Although not a recent concept, drug repurposing has gained momentum over the past few years and several drugs have been successfully repurposed. Here, we summarize the drug repurposing landscape from 2012 to 2017, with a major focus on repurposed drugs, collaborative opportunities, and funding opportunities specifi...


Case of drug-induced interstitial lung disease secondary to adalimumab.

In conjunction with will feature occasional drug-related cases that are likely to be of interest to readers. These will include cases that involve recently marketed drugs for which there is limited knowledge of adverse effects and cases that highlight unusual reactions to drugs that have been marketed for several years.

DrugCentral 2018: an update.

DrugCentral is a drug information resource (http://drugcentral.org) open to the public since 2016 and previously described in the 2017 Nucleic Acids Research Database issue. Since the 2016 release, 103 new approved drugs were updated. The following new data sources have been included: Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), FDA Orange Book information, L1000 gene perturbation profile distance/similarity matrices and estimated protonation constants. New and existing entries...


Biosimilar medicines used for cancer therapy in Europe: a review.

This article provides an updated review of the biosimilar medicines approved for cancer therapy in the European Union (EU). First we discuss the most relevant aspects for the development and approval of biosimilar medicines. We then present the oncological biosimilar drugs currently used, which include epoetins (alpha and zeta), filgrastim, and monoclonal antibodies (rituximab, trastuzumab and bevacizumab). Among the clinical applications of biosimilar medicines, cancer therapy remains the main target area ...

Dose-Finding Studies Among Orphan Drugs Approved in the EU: A Retrospective Analysis.

In the development process for new drugs, dose-finding studies are of major importance. Absence of these studies may lead to failed phase 3 trials and delayed marketing authorization. In our study we investigated to what extent dose-finding studies are performed in the case of orphan drugs for metabolic and oncologic indications. We identified all orphan drugs that were authorized until August 1, 2017. European Public Assessment Reports were used to extract the final dose used in the summary of product char...

Correction to: Reassessing Coronary Artery Bypass Surgery Versus Percutaneous Coronary Intervention in Patients with Type 2 Diabetes Mellitus: A Brief Updated Analytical Report (2015-2017).

In the original publication, conclusion was incorrectly updated in the article main text. The complete statement is given below.

Inhibition of ABCB1 and ABCG2 at the mouse blood-brain barrier with marketed drugs to improve brain delivery of the model ABCB1/ABCG2 substrate 11Cerlotinib.

P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) are two efflux transporters at the blood-brain barrier (BBB), which effectively restrict brain distribution of diverse drugs, such as tyrosine kinase inhibitors. There is a crucial need for pharmacological ABCB1 and ABCG2 inhibition protocols for a more effective treatment of brain diseases. In the present study, seven marketed drugs (osimertinib, erlotinib, nilotinib, imatinib, lapatinib, pazopanib and cyclosporine A) and one non-marketed ...

Early Childhood Education Centers' Reported Readiness to Implement the Updated Child and Adult Care Food Program Meal Pattern Standards in the United States, 2017.

The Child and Adult Care Food Program (CACFP) serves nutritious meals/snacks to >3.6 million children in early childhood education (ECE) centers. This study provides a nationwide assessment of nonhome-based CACFP-participating ECE centers' awareness of and reported readiness for implementing updated CACFP standards/best practices that took effect October 1, 2017.

Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.

Antihypertensive drugs are often used in the belief that lowering blood pressure will prevent progression to more severe disease, and thereby improve pregnancy outcome. This Cochrane Review is an updated review, first published in 2001 and subsequently updated in 2007 and 2014.

Current and future priorities for the development of optimal HIV drugs.

To summarize global efforts to accelerate access to simpler, safer and more affordable antiretroviral drugs and how this has shaped HIV treatment policy over the last decade, and outline future priorities. Several expert consultations aimed at aligning opportunities for optimization of antiretroviral drugs have been convened by WHO in partnership with academic institutions, international agencies, innovators and manufacturers. The increased access to lifelong treatment for people living with HIV also brings...

The Action of the Hexokinase Inhibitor 2-deoxy-D-glucose on Cryptosporidium parvum and the Discovery of Activities against the Parasite Hexokinase from Marketed Drugs.

Cryptosporidium parvum is one of the major species causing mild to severe cryptosporidiosis in humans and animals. We have previously observed that 2-deoxy-D-glucose (2DG) could inhibit both the enzyme activity of C. parvum hexokinase (CpHK) and the parasite growth in vitro. However, the action and fate of 2DG in C. parvum was not fully investigated. In the present study, we showed that, although 2DG could be phosphorylated by CpHK to form 2DG-6-phosphate (2DG6P), the anti-cryptosporidial activity of 2DG wa...

Comparing Two Classification Schemes for Seizures and Epilepsy in Rural China.

The International League Against Epilepsy (ILAE) updated the classifications of seizures and epilepsies in 2017. We compared the 2017 classifications with the 1980's classifications in rural China.

Increased Methamphetamine, Injection Drug, and Heroin Use Among Women and Heterosexual Men with Primary and Secondary Syphilis - United States, 2013-2017.

During 2013-2017, the national annual rate of reported primary and secondary (P&S) syphilis cases in the United States increased 72.7%, from 5.5 to 9.5 cases per 100,000 population (1). The highest rates of P&S syphilis are seen among gay, bisexual, and other men who have sex with men (collectively referred to as MSM) (2), and MSM continued to account for the majority of cases in 2017 (1). However, during 2013-2017, the P&S syphilis rate among women increased 155.6% (from 0.9 to 2.3 cases per 100,000 women)...

Generic Drugs in the United States: Policies to Address Pricing and Competition.

The cost of prescription drugs in the U.S. continues to be a source of concern for patients, caregivers, and policymakers. Drug prices typically decline rapidly once generic drugs receive U.S. Food and Drug Administration (FDA) approval and enter the market, but the past decade has witnessed rising costs and shortages of generic drugs. We describe the strategies employed by brand-name manufacturers to undermine generic competition and the reasons underlying the price increases of off-patent drugs, some of w...

Challenging MDR-TB clinical problems- the case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs.

MDR-TB is a growing challenge worldwide, and an obstacle to TB elimination. It is apparent that TB is being replaced by small but growing number of resistant cases with an anticipated 2 million cases of MDR-TB within the next two decades. One of the potential causes of MDR-TB is iatrogenic and we risk losing our new drugs through inexperience and repetition of basic errors of adding single active drugs to failing regimens. Discussion of MDR-TB cases with senior colleagues is not only best practice; it is no...

How far have we come? challenges to orphan drugs access in China, 2011-2017.

Rare diseases are an important global public health issue. One significant challenge is to ensure the access to orphan drugs for rare-disease patients. This study aims to evaluate the accessibility of orphan drugs in China.

The changing landscape of naloxone availability in the United States, 2011 - 2017.

Opioid overdose deaths have been on the rise in the United States since 1999. Naloxone is a competitive opioid antagonist that rapidly reverses opioid overdose. The implementation of naloxone access laws and development of naloxone formulations that can be administered by laypersons have coincided with changes in the landscape of naloxone availability in the United States. Using data from IQVIA's National Prescription Audit we present the number of naloxone prescriptions dispensed quarterly from 2011 throug...

Unique device identification and traceability for medical software: A major challenge for manufacturers in an ever-evolving marketplace.

Similarly to what already established and implemented in the United States, the concept of the Unique Device Identification (UDI) system has been introduced with the European Regulations for medical devices MDR (EU) 2017/745 and in-vitro diagnostic medical devices IVDR (EU) 2017/746 and it is on the way to become a worldwide standard. The aim of this work was to provide a possible approach for the implementation of UDI and traceability in Europe for standalone software medical devices according to lifecycle...

An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib.

Hepatocellular carcinoma (HCC) remains among the neoplastic diseases with the most unfavorable prognosis. Historically, systemic treatments for HCC have been scarce. In particular, sorafenib was the only registered drug for the treatment of unresectable HCC until 2017. Last year, regorafenib was approved by the global regulatory agencies as second-line therapy. Since then, further randomized, controlled trials have been successful in this patient population. This paper deals with the most recent data concer...

Implementing an Updated "Break the Cycle" Intervention to Reduce Initiating Persons into Injecting Drug Use in an Eastern European and a US "opioid epidemic" Setting.

We tested the hypothesis that an updated "Break the Cycle" (BtC) intervention, based in social cognitive theory and motivational interviewing, would reduce the likelihood that current persons who inject drugs (PWID) would assist persons who do not inject drugs (non-PWID) with first injections in Tallinn, Estonia and Staten Island, New York City. 402 PWID were recruited, a baseline interview covering demographics, drug use, and assisting non-PWID with first drug injections was administered, followed by BtC i...

Pharmaceutical cocrystals: from serendipity to design to application.

The field of pharmaceutical cocrystals has reached a tipping point, particularly because cocrystals can improve the physicochemical properties of drugs without compromising their therapeutic benefit. Accounts of cocrystal investigations in the literature started in earnest in 2003 and patent applications soon followed. The frequency of both has steadily accelerated, demonstrating an enhanced understanding of the design, characterisation, and manufacture of cocrystals and heightened interest from industry. I...

Development and validation of stability indicating reversed-phase liquid chromatographic method for simultaneous quantification of Methotrexate and Teriflunomide in nanoparticles and marketed formulation.

Methotrexate (MTX) and Teriflunomide (TEF) are the two most effective disease modifying antirheumatic drugs (DMARDs) used as combination therapy for rheumatoid arthritis (RA) and there is no as such robust high performance liquid chromatography (HPLC) method is available for their simultaneous estimation till date. Therefore, we have developed and validated an isocratic reversed-phase HPLC (RP-HPLC) method for simultaneous analysis of MTX and TEF spiked in the form of active pharmaceutical ingredients (APIs...

Correction: Landscape drivers of recent fire activity (2001-2017) in south-central Chile.

[This corrects the article DOI: 10.1371/journal.pone.0201195.].

Overall survival and updated progression-free survival outcomes in a randomized phase 2 study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.

Olaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor and cediranib is an oral anti-angiogenic. In the primary analysis of this phase 2 study, combination cediranib/olaparib improved progression-free survival (PFS) compared to olaparib alone in relapsed platinum-sensitive ovarian cancer. This updated analysis was conducted to characterize overall survival (OS) and update PFS outcomes.

New drugs creating new challenges in acute myeloid leukemia.

The therapeutic landscape is rapidly changing, with 8 new drugs approved by the Food and Drug Administration within the last 2 years, including midostaurin and gilteritinib for FLT3 mutant newly diagnosed and relapsed/refractory (R/R) acute myeloid leukemia (AML), respectively; CPX-351 (liposomal cytarabine and daunorubicin) for therapy-related AML and AML with myelodysplasia-related changes; gemtuzumab ozogamicin (anti-CD33 monoclonal antibody conjugated with calicheamicin) for newly diagnosed and R/R CD33...


Advertisement
Quick Search
Advertisement
Advertisement